

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

11-9-60 Dm

Applicants:

Michael Caplan

Serial No.:

09/247,406

Art Unit:

NOV 09 2000

Filed:

February 10, 1999

Examiner:

TECH CENTER 1600/2900

For:

METHOD FOR ALTERING UNDESIRABLE IMMUNE RESPONSES TO

**POLYPEPTIDES** 

Assistant Commissioner for Patents Washington, D.C. 20231

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicant submits a Supplemental Information Disclosure Statement, including two (2) page of Form PTO-1449, copies of the documents cited therein, and a copy of the International Search Report, mailed September 19, 2000, in the corresponding PCT application PCT/US00/03448.

It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 01-2507.

# Certification Under 37 C.F.R. §1.97 (e)(1)

Each item of information contained in this Supplemental Information Disclosure

Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information

Disclosure Statement.

U.S.S.N.:

09/247,406

Filed:

February 10, 1999

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

## **Foreign Documents**

Number	Publication Date	<u>Patentee</u>	Country
WO 97/33910 A1	09-18-1997	The Rockefeller University	PCT
WO 98/06861 A2	02-19-1998	Agrivax Incorporated	PCT

#### **Publications**

SMITH & CHAPMAN, "Localization of antigenic sites on Der p 2 using oligonucleotide-directed mutagenesis targeted to predicted surface residues," *Clinical and Experimental Allergy* 27:593-99 (1997).

WIEDEMANN, et al., "Molecular and structural analysis of a continuous birch profilin epitope defined by a monoclonal antibody," *J Biol Chem* 271(47):29915-21 (1996).

#### Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicant invites the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicant is of the opinion that his claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,

Patrea L. Pabst

Reg. No. 31,284

Dated: November 2, 2000

ARNALL GOLDEN & GREGORY, LLP 2800 One Atlantic Center 1201 W. Peachtree Street Atlanta, Georgia 30309-3450 (404) 873-8794 (404) 873-8795 (fax) U.S.S.N.:

09/247,406

Filed:

February 10, 1999 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT





# TECH CENTER 1500

## Certificate of Mailing under 37 CFR §1.8(a)

I hereby certify that this Supplemental Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date:

November 2, 2000



Substitute for form 1449A/PTO		Соп	nplete if Known
INFORMATION DISCLOSUS STATEMENT BY APPLICAL (USE as many sheets as necessary)		Number	09/247,406 NOV 0 9 2000
	Filing Date		February 10, 1998 CH CENTER 1800 29
/ %	First Named	Inventor	Michael Caplan
0.0000	Group Art U	nit	1627
/ MOA A o some ?	Examiner Na	ame	T. Wessendorf
Shear 1 of 2	Attorney Do	cket Number	HS 105
PADEMARIN	U.S. PATENT DOCUME	ENTS	
	tentee or Applicant ed Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
(II KNOWI)			

					FOREIGN PATENT DOCUMENT	rs		
Examiner Initials*	Initials* No.1		Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
		Office.3	Number <sup>4</sup>	Kind Code⁵ (if known)	1			
		wo	97/33910	A1	The Rockefeller University	09-18-1997		
		wo	98/06861	A2	Agrivax Incorporated	02-19-1998		
,								
								<u> </u>
								<u></u>

Examine	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO			49A/PTO	Complete if Known RECEI				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/247,406	RECEIVE		
	O I P (use as many sheets as necessary)					TECH CENTER 1600		
(use as many sneets as necessary)			·	Filing Date	February 10, 199	February 10, 1999		
/ No	)/ o -			First Named Inventor	Michael Caplan			
\B. "0	V U 5	2000 📆		Group Art Unit	1627			
運		<b>3</b>		Examiner Name	T. Wessendorf			
Sheet &	2	of of	2	Attorney Docket Number	HS 105			
	ADEN	ARIN	<b>4</b>					
				NON PATENT LITERATURE DO				
Examiner's Initials*	Cite No.¹	i	tem (book, magazine, journal		rticle (when appropriate), title of the ate, page(s), volume-issue number(s) published			
				ntigenic sites on Der p 2 using o and Experimental Allergy 27:593	oligonucleotide-directed mutage 3-99 (1997).	nesis targeted		
			et al., "Molecular and struiol Chem 271(47):29915-		birch profilin epitope defined by	y a monoclonal		
•								

Examiner's	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant to place a check mark here if English language Translation is attached.